治疗早期阿尔茨海默症的新药为更好的治疗增添希望

澳大利亚卫生部门批准了一种可能减缓阿尔茨海默病进展的新药。（点击音频收听详细内容）

This illustration made available by the National Institute on Aging/National Institutes of Health depicts cells in an Alzheimer’s affected brain, with abnormal levels of the beta-amyloid protein clumping together to form plaques, brown, that collect between neurons and disrupt cell function. Abnormal collections of the tau protein accumulate and form tangles, blue, within neurons, harming synaptic communication between nerve cells. An experimental Alzheimer’s drug modestly slowed the brain disease’s inevitable worsening, researchers reported Tuesday, Nov. 29, 2022 - and the next question is how much difference that might make in people’s lives. Japanese drugmaker Eisai and its U.S. partner Biogen had announced earlier this fall that the drug lecanemab appeared to work, a badly needed bright spot after repeated disappointments in the quest for better Alzheimer’s treatments. (National Institute on Aging, NIH via AP) Credit: AP

澳大利亚治疗药物管理局批准了一种可能为阿尔茨海默病患者带来希望的新药。

阿尔茨海默病是最常见的失智症，影响着约60万名澳大利亚人。

研究人员表示，这种新药代表着我们在寻求更佳治疗方法的道路上迈出了重要一步。

（点击音频收听详细报道）

欢迎下载应用程序SBS Audio，订阅Mandarin。您也可以通过YouTube、Apple Podcasts、Spotify等平台随时收听SBS普通话音频内容。请在 YouTube 和 X 关注SBS中文，了解更多澳洲新闻。